QIAGEN expands access to state-of-the-art HPV screening in China through co-marketing agreement with KingMed Diagnostics
. - Agreement will make HPV testing more widely available throughout China - QIAGEN’s digene HPV Test is regarded as t…
. - Agreement will make HPV testing more widely available throughout China - QIAGEN’s digene HPV Test is regarded as t…
. - therascreen® EGFR Mutation Detection Kit RGQ approved in Japan, one of the leading markets for pairing diagnostics…
. - Net sales of $264.3 million (0%, -2% CER) reflect anticipated soft start to 2011, disruptions in Japan and other ma…
QIAGEN (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) and Abbott (ABT: NYSE) today announced that they have entered into…
QIAGEN N.V. (Nasdaq: QGEN; Frankfurt, Prime Standard: QIA) today announced the results of operations for the fourth quar…
Merck & Co., Inc. and QIAGEN N.V. today announced their intent to collaborate on a new program to increase access to HPV…
Results from an eight-year trial involving more than 130,000 women published today in The New England Journal of Medicin…
QIAGEN N.V. (Nasdaq: QGEN; Frankfurt, Prime Standard: QIA) today announced the results of operations for the second quar…
New cervical cancer prevention guidelines issued by the German Association for Gynecology and Obstetrics (DGGG) recommen…
QIAGEN Gaithersburg, Inc. (formerly Digene Corporation), a wholly-owned subsidiary of QIAGEN N.V. (NASDAQ: QGEN; Frankfu…